{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-204147","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.712545+00:00","generated_at":"2026-05-14T23:55:47.472401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR Q1 2026: net loss narrows to $122.9M; CASGEVY revenue $43M; cash at $2.44B","bullets":["Net loss of $122.9M vs $136.0M in Q1 2025; R&D spend $68.6M, G&A $17.2M.","CASGEVY revenue of $43M; collaboration expense net $45.9M, down on higher revenue share.","Cash, equivalents and securities $2,441.8M, up from $1,975.8M, boosted by $585.4M convertible note.","Zugo-cel started 3rd Phase 1 in autoimmune neurology; SLE patients remain in DORIS remission at Month 12 and Month 6.","In vivo CTX310 IND cleared for US; CTX460 (AATD) and CTX340 (hypertension) on track for mid-2026 and H1 2026 clinical starts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-204147","json":"https://secwatch.observer/filing/0001193125-26-204147.json","markdown":"https://secwatch.observer/filing/0001193125-26-204147.md","text":"https://secwatch.observer/filing/0001193125-26-204147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/0001193125-26-204147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/crsp-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:55:47.472401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe142f2c71da117fd9ed0daf986fbca4ffadc849","claim":"CRISPR Therapeutics AG reported first quarter 2026 results: revenue $43 million.","evidence_excerpt":"CASGEVY generated first quarter 2026 revenue of $43 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526204147/0001193125-26-204147-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Revenue","value":"$43 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}